临床 试验
- Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer条件:肺癌分子:Tislelizumab
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma条件:胃癌, 食道癌分子:Tislelizumab
- A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma条件:淋巴瘤分子:Tislelizumab
- Study of the Safety, Pharmacokinetics and Antitumor Activities of Tislelizumab in Subjects With Advanced Tumors条件:晚期实体肿瘤分子:Tislelizumab
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma条件:胶质母细胞瘤分子:Pamiparib + Radiotherapy and/or Temozolomide [1L] and Pamiparib + Temozolomide [R/R])
- Study to Assess Safety, Tolerability and Clinical Activity of Pamiparib in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors条件:晚期实体肿瘤分子:Pamiparib + Temozolomide
- The Safety, Pharmacokinetics and Antitumor Activity of Tislelizumab in Combination With Pamiparib in Subjects With Advanced Solid Tumors条件:晚期实体肿瘤分子:Tislelizumab + Pamiparib
- Study of Pamiparib or Placebo in Patients With Advanced or Inoperable Gastric Cancer条件:胃癌分子:Pamiparib
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Pamiparib Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer条件:卵巢癌分子:Pamiparib
- Efficacy and Safety of Pamiparib in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China条件:乳腺癌分子:Pamiparib